by PEPID Newsroom | Mar 19, 2019 | Alerts
Tuesday, March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use to treat post-partum depression (PPD) in adult women. No other drug before now has been approved to specifically treat PPD. Zulresso will be available through Risk Evaluation...
by PEPID Newsroom | Mar 14, 2019 | Alerts
The Food and Drug Administration (FDA) has allowed marketing of ClearMate to treat patients suffering from carbon monoxide poisoning in emergency rooms. Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat Devices in the FDA’s...
by PEPID Newsroom | Mar 14, 2019 | Alerts
As of March 12, 2019 the U.S. FDA approved a new generic of Diovan (valsartan) for high blood pressure and heart failure to relieve the shortage from multiple recalls of generic valsartan products from several manufacturers. The approval of the new generic of Diovan...
by PEPID Newsroom | Mar 6, 2019 | Alerts
Measles, also known as rubeola or “first disease”, is a highly contagious viral infection caused by paramyxovirus, causing a prodrome of fever, cough, coryza, and conjunctivitis followed by eruption of maculopapular rash. The CDC states 2 main reasons for the increase...
by PEPID Newsroom | Feb 27, 2019 | Alerts
CDC published a report today that provides the most recent data on HIV trends in America from 2010 to 2016. The results show a stagnation in the decline of HIV infections, with numbers of HIV Infections leveling off at about 39,000. When taking a deeper dive into the...
by PEPID Newsroom | Jan 28, 2019 | Alerts
Public Officials in Clark County, Washington are investigating a measles outbreak after reports of 34 confirmed cases and nine suspected cases since the first of January. Of the 34 cases, thirty-two have been confirmed to be unimmunized, while four remain unverified....
by PEPID Newsroom | Jan 2, 2019 | Alerts
The injection Ultomirus (ravulizumab) has been approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is a long-acting complement inhibitor that prevents hemolysis. Richard Pazdur, M.D., director of the FDA’s Oncology...
by PEPID Newsroom | Jan 2, 2019 | Alerts
The FDA has approved Elxonris (tagraxofusperzs) infusion to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients two years and older. This is the first FDA approved therapy specifically for BPDCN. Elzonris is a targeted investigational therapy...
by PEPID Newsroom | Dec 27, 2018 | Alerts
FDA approved ProAir digihaler by Asthmapolis, the first app-connected digital inhaler. The ProAir Digihaler has built-in sensors to detect when the device is used and the strength of the user’s inhalation. This data is then sent via Bluetooth to its mobile app...
by PEPID Newsroom | Dec 17, 2018 | Alerts
There’s a new drug for people suffering from Chronic Idiopathic Constipation(CIC) headed to the market in 2019. The US FDA has approved Motegrity with the active ingredient Prucalopride for the treatment of CIC presented by Shire Dev LLC. Motegrity is a...
by PEPID Newsroom | Dec 11, 2018 | Alerts
The Lancet reports the first successful live birth from a uterus transplant. In September 2016, a 32-year-old woman in Brazil with congenital uterine absence, or Mayer-Rokitansky-Küster-Hauser [MRKH] syndrome, underwent a successful uterine transplantation from a...
by PEPID Newsroom | Dec 10, 2018 | Alerts
FDA clears mobile medical app reSET-O to help opioid use disorder patients stay in recovery programs. This new method of treatment is a prescription cognitive behavioral therapy to be used in conjunction with treatment that includes buprenorphine and contingency...
by PEPID Newsroom | Nov 20, 2018 | Alerts
The FDA approved Aemcolo (rifamycin) yesterday for the treatment of travelers’ diarrhea. Aemcolo is an antibacterial drug to treat noninvasive strains of Escherichia coli (E. coli) not complicated by fever or blood in the stool. The FDA estimates 10-40% of travelers...
by PEPID Newsroom | Nov 14, 2018 | Alerts
FDA approves a new version of Primatene Mist, the only OTC metered-dose inhaler. Primatene Mist is approved by the FDA as an OTC drug to provide temporary relief for symptoms of mild, intermittent asthma. Primatene Mist is only approved for those who have been...
by Megan Pullins | Nov 14, 2018 | Alerts
Monday, JAMA published a summarized report of the just-released U.S. Department of Health and Human Services (HHS) second edition Physical Activity Guidelines for Americans (PAG), which provides evidence-based recommendations to improve American individual and...
